Zacks Research Decreases Earnings Estimates for Haemonetics

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research cut their Q3 2025 EPS estimates for shares of Haemonetics in a report issued on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $1.19 per share for the quarter, down from their previous estimate of $1.22. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.59 EPS, Q1 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.32 EPS, FY2026 earnings at $5.17 EPS and Q1 2027 earnings at $1.48 EPS.

Several other equities analysts have also recently weighed in on HAE. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research note on Friday, November 8th. Citigroup cut their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research report on Friday, November 8th. Finally, Bank of America started coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Stock Down 0.5 %

Shares of Haemonetics stock opened at $87.47 on Monday. The firm has a market cap of $4.39 billion, a PE ratio of 36.29, a P/E/G ratio of 1.36 and a beta of 0.32. The business’s 50 day simple moving average is $79.99 and its 200 day simple moving average is $82.05. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a 52-week low of $70.25 and a 52-week high of $97.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the business posted $0.99 EPS.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP lifted its stake in shares of Haemonetics by 9.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after buying an additional 363,702 shares during the last quarter. Royce & Associates LP grew its position in shares of Haemonetics by 2.6% in the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after purchasing an additional 30,868 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Haemonetics by 1.8% during the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after purchasing an additional 21,547 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Haemonetics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.